Intuitive Surgical

ISRG

Market cap $188B

Jobless Claims Come in Slightly Higher.

Weekly Jobless Claims continue to portray a labor market cruising along at a healthy low rate of unemployment claims.

Intuitive Surgical's newest model of its flagship device should make progress through 2031. The company will face a more competitive market moving forward.

Intuitive Surgical's pure-play robotics focus, rising da Vinci 5 utilization and 85% recurring revenues tilt the risk-reward versus diversified Medtronic.

Eli Lilly's stock price has underperformed this year, much of it on the back of drug pricing concerns, potential tariff impacts and, perhaps, less enthusiasm for GLP-1 drugs. The primary drag for the quarter was Oracle, accounting for almost all of the Portfolio's relative underperformance in Q4, completely reversing its performance from the prior quarter and giving back all of the gains experienced in Q3. Polen Capital initiated a 2.25% position in Intuitive Surgical who maintain a de facto monopoly in soft tissue robotic surgery globally.

ISRG heads into Q4 earnings with 18% procedure growth and da Vinci 5 demand, but valuation and tariffs keep the earnings outlook uncertain.

Active traders expect companies in the healthcare sector to experience significant share price spikes tied to milestones in the development of new therapies and medical products. The volatility in some corners of the sector makes it a high-risk, but high-reward, opportunity.

PODD is Intuitive Surgical's counterpart in the Health Care Equipment sector that has:

Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie's immunosuppressant portfolio helps it to produce steady revenue and profits.

Intuitive Surgical is positioning da Vinci 5 as a data-driven platform, using AI, software and surgical data to expand beyond robotics into insights.